Moderna Reports Settlement Agreement with Arbutus/Genevant
Summary
On March 3, 2026, Moderna, Inc. entered into a Settlement Agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH to resolve all worldwide patent infringement litigation related to Spikevax® and mRESVIA®. This agreement provides certainty for Moderna's full infectious disease portfolio, including mNEXSPIKE® and mCOMBRIAX®, with no future royalties owed. Moderna will make a $950 million noncontingent lump sum payment to Arbutus/Genevant on or before July 8, 2026. - An additional $1.3 billion contingent lump sum payment may be due if Moderna's appeal regarding 28 U.S.C. § 1498 is unsuccessful. - If Moderna prevails on its appeal, no further payments will be due.
Why It Matters
This settlement resolves significant patent litigation, providing clarity and certainty for Moderna's key vaccine products and future pipeline without ongoing royalty obligations. The agreement involves a substantial noncontingent payment of $950 million and a potential additional $1.3 billion, which will materially impact Moderna's financial outlook.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how MRNA traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View MRNA Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“and its future vaccine pipeline, with no future royalties owed. Under the terms of the Settlement Agreement, Moderna will make a $950 million noncontingent lump sum payment to Arbutus/Genevant on or before July 8, 2026.”
— From Item 1.01
Filing Details
Reported Items
Additional Information
- CIK Number
- 0001682852
- Filing Date
- Thursday, March 5, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- neutral